Managing macrophages in rheumatoid arthritis by reform or removal

Current Rheumatology Reports

Volumn 14, Issue 5, 2012, Pages 445-454

  Li, Jun ^a,b   Hsu, Hui Chen ^a   Mountz, John D ^a,b  

^a The University of Alabama at Birmingham   (United States)

^b BIRMINGHAM VA MEDICAL CENTER   (United States)

Author keywords

Depletion; Inflammation; Joint recruitment; Macrophage; Management; Polarization; Reform; Removal; Rheumatoid arthritis; Therapy; TRAIL

Indexed keywords

APOPTOTIC PROTEASE ACTIVATING FACTOR 1; CD163 ANTIGEN; CD68 ANTIGEN; CLODRONIC ACID; COLONY STIMULATING FACTOR 1; DEATH RECEPTOR 5; FAS ANTIGEN; FAS LIGAND; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOSOME; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BCL 2; PROTEIN KINASE B; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; X LINKED INHIBITOR OF APOPTOSIS;

APOPTOSIS; CELL ACTIVATION; CELL DIFFERENTIATION; CELL FUNCTION; CELL HETEROGENEITY; CELL LINEAGE; CELL SUBPOPULATION; COLONY FORMING UNIT GM; FIBROBLAST; GENETIC MODEL; HUMAN; IMMUNOREGULATION; INFLAMMATION; MACROPHAGE; MACROPHAGE DEPLETION; PHENOTYPE; POLARIZATION; PROTEIN EXPRESSION; PROTEIN INTERACTION; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SYNOVIUM;

ANIMALS; ANTIRHEUMATIC AGENTS; APOPTOSIS; ARTHRITIS, RHEUMATOID; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; HUMANS; MACROPHAGE ACTIVATION; MACROPHAGES; MICE; MICE, TRANSGENIC; SYNOVIAL MEMBRANE; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 84869210018     PISSN: 15233774     EISSN: 15346307     Source Type: Journal    
DOI: 10.1007/s11926-012-0272-4     Document Type: Review

References (54)

1. Mantovani A, Sica A, Sozzani S, et al. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol. 2004; 25: 677-86. (Pubitemid 39457982)
2. Mosser DM, Edwards JP. Exploring the full spectrum of macrophage activation. Nat Rev Immunol. 2008; 8: 958-69.
3. Hamilton JA. Colony-stimulating factors in inflammation and autoimmunity. Nat Rev Immunol. 2008; 8: 533-44. (Pubitemid 351913679)
4. Hashimoto D, Miller J, Merad M. Dendritic cell and macrophage heterogeneity in vivo. Immunity. 2011; 35: 323-35. The authors discuss how recent discoveries in the origin of the DC and macrophage lineage help establish key functional differences between tissue DC and macrophage subsets. The authors also emphasize the need to further understand the functional heterogeneity of the tissue DC and macrophage lineages to better comprehend the complex role of these cells in tissue homeostasis and immunity.
5. Hamilton JA, Tak PP. The dynamics of macrophage lineage populations in inflammatory and autoimmune diseases. Arthritis Rheum. 2009; 60: 1210-21. This is one of the most comprehensive review discussing the macrophage heterogeneity in autoimmunity.
6. Chow A, Brown BD, MeradM. Studying the mononuclear phagocyte system in the molecular age. Nat Rev Immunol. 2011; 11: 788-98.
7. Campbell IK, Rich MJ, Bischof RJ, et al. The colony-stimulating factors and collagen-induced arthritis: Exacerbation of disease by m-csf and g-csf and requirement for endogenous m-csf. J Leukoc Biol. 2000; 68: 144-50.
8. Cook AD, Braine EL, Campbell IK, et al. Blockade of collageninduced arthritis post-onset by antibody to granulocyte-macrophage colony-stimulating factor (gm-csf): Requirement for gm-csf in the effector phase of disease. Arthritis Res. 2001; 3: 293-8. (Pubitemid 32821522)
9. Ohno H, Uemura Y, Murooka H, et al. The orally-active and selective c-fms tyrosine kinase inhibitor ki20227 inhibits disease progression in a collagen-induced arthritis mouse model. Eur J Immunol. 2008; 38: 283-91.
10. Ando W, Hashimoto J, Nampei A, et al. Imatinib mesylate inhibits osteoclastogenesis and joint destruction in rats with collagen-induced arthritis (cia). J Bone Miner Metab. 2006; 24: 274-82. (Pubitemid 43992670)
11. Cornish AL, Campbell IK, McKenzie BS, et al. G-CSF and GMCSF as therapeutic targets in rheumatoid arthritis. Nat Rev Rheumatol. 2009; 5: 554-9. The authors postulate that antagonism of GCSF or GM-CSF could represent a novel therapeutic approach for a variety of autoimmune-mediated inflammatory diseases, including rheumatoid arthritis.
12. Anna Yarilina KX, Chan C, et al. Regulation of macrophagemediated chronic inflammation by jak inhibitors. Arthritis Res Ther. 2012; 14: 53-4.
13. Park-Min KH, Ji JD, Antoniv T, et al. IL-10 suppresses calciummediated costimulation of receptor activator nf-kappa b signaling during human osteoclast differentiation by inhibiting trem-2 expression. J Immunol. 2009; 183: 2444-55.
14. Lee SM, Suk K, Lee WH. Synthetic peptides containing itim-like sequences of irem-1 (cd300f) differentially regulate myd88 and trif-mediated tlr signalling through activation of shp and/or pi3k. Clin Exp Immunol. 2012; 167: 438-46. The authors describe the generation of immunomodulatory molecules that can regulate the inflammatory activation of macrophages.
15. Ruhmann M, Piccinini AM, Kong PL, et al. Endogenous activation of adaptive immunity: Tenascin-c drives il-17 synthesis in arthritic joint disease. Arthritis Rheum. 2012.
16. Kokkonen H, Soderstrom I, Rocklov J, et al. Up-regulation of cytokines and chemokines predates the onset of rheumatoid arthritis. Arthritis Rheum. 2010; 62: 383-91. The data show that prior to development of RA, "prepatient" individuals already had significantly increased levels of GM-CSF, M-CSF, and other proinflammatory cytokines and chemokines, indicating activation of the immune. system, as compared with controls, who did not develop RA. After disease onset, the involvement and activation of the immune system was more general and widespread.
17. Mulherin D, Fitzgerald O, Bresnihan B. Synovial tissue macrophage populations and articular damage in rheumatoid arthritis. Arthritis Rheum. 1996; 39: 115-24. (Pubitemid 26036386)
18. Ramprasad MP, Terpstra V, Kondratenko N, et al. Cell surface expression of mouse macrosialin and human cd68 and their role as macrophage receptors for oxidized low density lipoprotein. Proc Natl Acad Sci USA. 1996; 93: 14833-8. (Pubitemid 26419055)
19. Strobl H, Scheinecker C, Csmarits B, et al. Flow cytometric analysis of intracellular cd68 molecule expression in normal and malignant haemopoiesis. Br J Haematol. 1995; 90: 774-82.
20. Haringman JJ, Gerlag DM, Zwinderman AH, et al. Synovial tissue macrophages: A sensitive biomarker for response to treatment in patients with rheumatoid arthritis. Ann Rheum Dis. 2005; 64: 834-8. (Pubitemid 40733904)
21. Van Gorp H, Delputte PL, Nauwynck HJ. Scavenger receptor CD163, a jack-of-all-trades and potential target for cell-directed therapy. Mol Immunol. 2010; 47: 1650-60.
22. Philippidis P, Mason JC, Evans BJ, et al. Hemoglobin scavenger receptor cd163 mediates interleukin-10 release and heme oxygenase-1 synthesis: antiinflammatory monocyte-macrophage responses in vitro, in resolving skin blisters in vivo, and after cardiopulmonary bypass surgery. Circ Res. 2004; 94: 119-26. (Pubitemid 38064106)
23. Fonseca JE, Edwards JC, Blades S, et al. Macrophage subpopulations in rheumatoid synovium: Reduced cd163 expression in cd4+ t lymphocyte-rich microenvironments. Arthritis Rheum. 2002; 46: 1210-6. (Pubitemid 34525827)
24. Bleesing J, Prada A, Siegel DM, et al. The diagnostic significance of soluble cd163 and soluble interleukin-2 receptor alpha-chain in macrophage activation syndrome and untreated new-onset systemic juvenile idiopathic arthritis. Arthritis Rheum. 2007; 56: 965-71. (Pubitemid 46399444)
25. Ambarus CA, Krausz S, van Eijk M, et al. Systematic validation of specific phenotypic markers for in vitro polarized human macrophages. J Immunol Methods. 2011; 375: 196-206.
26. Krausgruber T, Blazek K, Smallie T, et al. Irf5 promotes inflammatory macrophage polarization and th1-th17 responses. Nat Immunol. 2011; 12: 231-8. The data suggest a critical role for IRF5 in M1 macrophage polarization and define a previously unknown function for IRF5 as a transcriptional repressor.
27. Li J, Hsu HC, Yang P, et al. Treatment of arthritis by macrophage depletion and immunomodulation: testing an apoptosis-mediated therapy in a humanized death receptor mouse model. Arthritis Rheum. 2012; 64: 1098-109. This is the first demonstration and proof of the principle that an anti-human DR5 apoptosis therapy can be used to prevent and treat arthritis in a CIA mouse model. The authors utilized a novel hu/mo chimeric DR5 mouse to demonstrate the efficacy of an antihuman DR5 therapy and showed that induction of apoptosis of macropghages was the major mechanism of action leading to decreased inflammatory macrophages and Th17 cells and increased Treg cells.
28. Parihar A, Eubank TD, Doseff AI. Monocytes and macrophages regulate immunity through dynamic networks of survival and cell death. J Innate Immun. 2010; 2: 204-15. This review summarizes the contribution of the caspases and their regulators in monocyte/macrophage cell fate and discusses how these molecules orchestrate the initiation, maintenance, and resolution of inflammation. More provocatively, we discuss possible strategies for controling inflammation by manipulating leukocyte life span.
29. Zhou T, Edwards 3rd CK, Yang P, et al. Greatly accelerated lymphadenopathy and autoimmune disease in lpr mice lacking tumor necrosis factor receptor i. J Immunol. 1996; 156: 2661-5. (Pubitemid 126660608)
30. Jacob CO, Aiso S, Michie SA, et al. Prevention of diabetes in nonobese diabetic mice by tumor necrosis factor (tnf): similarities between tnf-alpha and interleukin 1. Proc Natl Acad Sci USA. 1990; 87: 968-72.
31. Parameswaran N, Patial S. Tumor necrosis factor-alpha signaling in macrophages. Crit Rev Eukaryot Gene Expr. 2010; 20: 87-103.
32. Catrina AI, Trollmo C. af Klint E, et al. Evidence that antitumor necrosis factor therapy with both etanercept and infliximab induces apoptosis in macrophages, but not lymphocytes, in rheumatoid arthritis joints: extended report. Arthritis Rheum. 2005; 52: 61-72. (Pubitemid 40129233)
33. Taylor PC, Peters AM, Paleolog E, et al. Reduction of chemokine levels and leukocyte traffic to joints by tumor necrosis factor alpha blockade in patients with rheumatoid arthritis. Arthritis Rheum. 2000; 43: 38-47. (Pubitemid 30368211)
34. Ehrenstein MR, Evans JG, Singh A, et al. Compromised function of regulatory t cells in rheumatoid arthritis and reversal by antitnfalpha therapy. J Exp Med. 2004; 200: 277-85. (Pubitemid 39031247)
35. Singh JA, Beg S. Lopez-Olivo MA Tocilizumab for rheumatoid arthritis: a cochrane systematic review. J Rheumatol. 2011; 38: 10-20.
36. Bluml S, Binder NB, Niederreiter B, et al. Antiinflammatory effects of tumor necrosis factor on hematopoietic cells in a murine model of erosive arthritis. Arthritis Rheum. 2010; 62: 1608-19. The data indicate that selective blockade of TNFRI, leaving the antiinflammatory effects of TNFRII unaltered instead of unselectively blocking TNF, might be advantageous in patients with RA.
37. Takahashi T, Tanaka M, Brannan CI, et al. Generalized lymphoproliferative disease in mice, caused by a point mutation in the fas ligand. Cell. 1994; 76: 969-76. (Pubitemid 24106378)
38. Watanabe-Fukunaga R, Brannan CI, Copeland NG, et al. Lymphoproliferation disorder in mice explained by defects in fas antigen that mediates apoptosis. Nature. 1992; 356: 314-7.
39. Stranges PB, Watson J, Cooper CJ, et al. Elimination of antigenpresenting cells and autoreactive t cells by fas contributes to prevention of autoimmunity. Immunity. 2007; 26: 629-41. (Pubitemid 46756349)
40. Cuda CM, Agrawal H, Misharin AV, et al. Requirement of myeloid cell-specific fas expression for prevention of systemic autoimmunity in mice. Arthritis Rheum. 2012; 64: 808-20.
41. Burnett SH, Kershen EJ, Zhang J, et al. Conditional macrophage ablation in transgenic mice expressing a fas-based suicide gene. J Leukoc Biol. 2004; 75: 612-23. (Pubitemid 38405652)
42. Fleetwood AJ, Dinh H, Cook AD, Hertzog PJ, Hamilton JA. GM-CSF- and M-CSF-dependent macrophage phenotypes display differential dependence on type I interferon signaling. J Leukoc Biol. 2009; 86: 411-21. The findings demonstrate that constitutive and LPS-induced type I IFN play significant roles in regulating the differences in phenotype and function between M-CSF-induced macrophages and GM-CSF-induced macrophages.
43. Perlman H, Nguyen N, Liu H, et al. Rheumatoid arthritis synovial fluid macrophages express decreased tumor necrosis factor-related apoptosis-inducing ligand r2 and increased decoy receptor tumor necrosis factor-related apoptosis-inducing ligand r3. Arthritis Rheum. 2003; 48: 3096-101. (Pubitemid 37409320)
44. Ichikawa K, Liu W, Fleck M, et al. TRAIL-R2 (DR5) mediates apoptosis of synovial fibroblasts in rheumatoid arthritis. J Immunol. 2003; 171: 1061-9. (Pubitemid 36871423)
45. Lawlor KE, Smith SD, van Nieuwenhuijze A, et al. Evaluation of the bcl-2 family antagonist abt-737 in collagen-induced arthritis. J Leukoc Biol. 2011; 90: 819-29.
46. Perlman H, Georganas C, Pagliari LJ, et al. Bcl-2 expression in synovial fibroblasts is essential for maintaining mitochondrial homeostasis and cell viability. J Immunol. 2000; 164: 5227-35. (Pubitemid 30305200)
47. Liu H, Eksarko P, Temkin V, et al. Mcl-1 is essential for the survival of synovial fibroblasts in rheumatoid arthritis. J Immunol. 2005; 175: 8337-45. (Pubitemid 41798400)
48. Liu H, Huang Q, Shi B, et al. Regulation of mcl-1 expression in rheumatoid arthritis synovial macrophages. Arthritis Rheum. 2006; 54: 3174-81. (Pubitemid 44622088)
49. Barrera P, Blom A, van Lent PL, et al. Synovial macrophage depletion with clodronate-containing liposomes in rheumatoid arthritis. Arthritis Rheum. 2000; 43: 1951-9.
50. Hochweller K, Striegler J, Hammerling GJ, et al. A novel CD11c.DTR transgenic mouse for depletion of dendritic cells reveals their requirement for homeostatic proliferation of natural killer cells. Eur J Immunol. 2008; 38: 2776-83.
51. Moss ML, Sklair-Tavron L, Nudelman R, et al. Tumor necrosis factor-converting enzyme as a pharmaceutical target for rheumatoid arthritis. Nat Clin Pract Rheumatol. 2008; 4: 300-9. (Pubitemid 351791441)
52. Walker UA. More about masitinib. Arthritis Res Ther. 2009; 11: 120.
53. Paniagua RT, Robinson WH. Imatinib for the treatment of rheumatic diseases. Nat Clin Pract Rheumatol. 2007; 3: 190-1. (Pubitemid 46860398)
54. Reich K, Yasothan U, Kirkpatrick P. Ustekinumab. Nat Rev Drug Discov. 2009; 8: 355-6.